Theravance Biopharma (TBPH) Consolidated Net Income (2016 - 2025)
Historic Consolidated Net Income for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to $3.6 million.
- Theravance Biopharma's Consolidated Net Income rose 12846.91% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.8 million, marking a year-over-year increase of 14415.3%. This contributed to the annual value of -$64.0 million for FY2024, which is 1594.04% down from last year.
- Latest data reveals that Theravance Biopharma reported Consolidated Net Income of $3.6 million as of Q3 2025, which was up 12846.91% from $54.8 million recorded in Q2 2025.
- In the past 5 years, Theravance Biopharma's Consolidated Net Income registered a high of $927.1 million during Q3 2022, and its lowest value of -$23.1 million during Q4 2024.
- For the 5-year period, Theravance Biopharma's Consolidated Net Income averaged around $50.3 million, with its median value being $3.6 million (2025).
- Per our database at Business Quant, Theravance Biopharma's Consolidated Net Income skyrocketed by 440000.49% in 2022 and then crashed by 31854.13% in 2023.
- Theravance Biopharma's Consolidated Net Income (Quarter) stood at $25.8 million in 2021, then crashed by 84.9% to $3.9 million in 2022, then crashed by 318.54% to -$8.5 million in 2023, then tumbled by 171.45% to -$23.1 million in 2024, then skyrocketed by 115.65% to $3.6 million in 2025.
- Its Consolidated Net Income was $3.6 million in Q3 2025, compared to $54.8 million in Q2 2025 and -$13.5 million in Q1 2025.